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Nonrandomized studies are usually excluded from systematic reviews. This could lead to loss of
a considerable amount of information on rare diseases. In this article, we explore the impact of
excluding nonrandomized studies on the generalizability of meta-analyses results on
mucopolysaccharidosis (MPS) disease. A comprehensive search of systematic reviews on
MPS patients up to May 2020 was carried out (CRD42020191217). The primary endpoint was
the rate of patients excluded from systematic reviews if only randomized studies were
considered. Secondary outcomes included the differences in patient and study
characteristics between randomized and nonrandomized studies, the methods used to
combine data from studies with different designs, and the number of patients excluded
from systematic reviews if case reports were not considered. More than 50% of the
patients analyzed have been recruited in nonrandomized studies. Patient characteristics,
duration of follow-up, and the clinical outcomes evaluated differ between the randomized
and nonrandomized studies. There are feasible strategies to combine the data from different
randomized and nonrandomized designs. The analyses suggest the relevance of including case
reports in the systematic reviews, since the smaller the number of patients in the reference
population, the larger the selection bias associated to excluding case reports. Our results
recommend including nonrandomized studies in the systematic reviews of MPS to increase the
representativeness of the results and to avoid a selection bias. The recommendations obtained
from this study should be considered when conducting systematic reviews on rare diseases.
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INTRODUCTION
The randomized clinical trials provide the strongest evidence
regarding the efficacy of new therapeutic interventions (Higgins
et al., 2019). Thus, they must be eligible for systematic reviews. On
the contrary, nonrandomized designs, in addition to different design
features, are variable in their susceptibility to bias (Reeves et al.,
2017). Empirical evidence suggests that the observational studies are
considered less rigorous, without a preplanned statistical analysis
plan, with a higher risk of selection bias, and more affected by
confounding than randomized clinical trials (Higgins et al., 2019;
Morgan et al., 2019). Furthermore, the systematic review guidelines
recommend that both randomized and nonrandomized studies with
different design features should be analyzed separately (Higgins
et al., 2019). Accordingly, nonrandomized studies and case reports
are excluded from systematic reviews and only considered when
there are no other design alternatives (Catalá-López et al., 2017;
Pérez-López et al., 2017; Sampayo-Cordero et al., 2018; Sampayo-
Cordero et al., 2019).
In the field of rare diseases, and specifically in
mucopolysaccharidosis (MPS), the low prevalence of the
disease makes the possibility of performing randomized
clinical trials extremely difficult. Additionally, clinical trials
usually include a relatively more homogeneous population
according to predefined characteristics than clinical practice.
Thus, the phenotypic and genotypic heterogeneity increases
the difficulty to generalize the efficacy results from a clinical
trial (Kahan et al., 2015; Frieden, 2017; Hong et al., 2018).
Previous systematic reviews have stated that observational
studies properly conducted could achieve evidence equivalent
to that of randomized clinical trials (Concato et al., 2000;
Sampayo-Cordero et al., 2018; Sampayo-Cordero et al., 2019).
It is increasingly recognized that subject selection criteria and
monitoring conditions of clinical trials usually differ from clinical
practice, while prospective studies and case reports are nearer to
standard clinical practice conditions (Kahan et al., 2015; Hong
et al., 2018; on behalf of the ACMG Professional Practice and
Guidelines Committee et al., 2020). Therefore, the exclusion of
patients from nonrandomized studies and case reports could
reduce the generalization of the meta-analyses results and
introduce a selection bias in the study. Moreover, different
methods have been proposed to combine information
provided by clinical trials, clinical studies, and case reports
(Bradley et al., 2017; Dornelles et al., 2017; Pérez-López et al.,
2017, Pérez-López et al., 2018).
Previous systematic reviews on patients with MPS have
evaluated the efficacy and safety of enzyme replacement
therapies (ERTs). However, the selection strategies among
different revisions and meta-analyses are quite heterogeneous.
Some studies included only randomized trials and others allowed
for the selection of different types of nonrandomized designs
(Schrover et al., 2017; Gomes et al., 2019; Jameson et al., 2019).
Our proposal is to carry out a systematic review of meta-
analyses that includes randomized or nonrandomized studies in
MPS that evaluate the efficacy or safety of ERTs. The aim of the
present study is to explore the impact of excluding
nonrandomized studies on the generalizability of the meta-
analysis results and the probability of selection bias.
Additionally, we report the methods used to combine data
from different study designs.
MATERIALS AND METHODS
Data Sources and Searches
A comprehensive search of systematic reviews containing
clinical information of MPS patients up to May 2020 was
carried out on MEDLINE, the Cochrane Library (Cochrane
Database of Systematic Reviews and protocols), and the
International Prospective Register of Systematic Reviews
(PROSPERO) databases as well as on the Latin American
and Caribbean Literature on Health Sciences (LILACS). The
search strategy retrieved citations from the MEDLINE database
containing the “All fields” headings: “mucopolysaccharidosis”
and “systematic review”. In the Cochrane Library, the strategy
retrieved citations containing the “complete text” headings:
“mucopolysaccharidosis”. The search strategy for the PROSPERO
database retrieved citations containing the heading:
“mucopolysaccharidosis”. Finally, the search strategy for
the LILACS database retrieved citations containing the
“Title, Summary, Issue” headings: “mucopolysaccharidosis”
and “systematic review”. There was no restriction of dose,
treatment duration, administration (via intravenous or
intrathecal), type of study design, or language. All
published studies up to May 20, 2020, were included in the
search.
Study Selection
The original articles of the systematic reviews selected by an
electronic search were obtained and reviewed. We selected
those systematic reviews meeting the following selection
criteria:
Inclusion Criteria
a) Systematic reviews of nonrandomized and/or randomized
studies conducted in patients with MPS.




b) Systematic reviews evaluating pharmacoeconomic endpoints,
preclinical evaluations, or incidence of MPS.
c) Systematic reviews evaluating only hematopoietic stem cell
transplantation.
Quality Assessment
The study was prospectively designed to describe the methods
used in MPS systematic reviews. The current meta-analysis
is reported in accordance with the preferred reporting
items for systematic reviews and meta-analysis (PRISMA)
and meta-analyses and systematic reviews of observational
studies (MOOSE) guidelines (Stroup et al., 2000; Liberati
et al., 2009; Page and Moher, 2017). The protocol was
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published in the PROSPERO database (CRD42020191217).
Two investigators entered findings into a database,
independently reviewed citations/abstracts from the
database and hand-searched and selected full relevant
articles and documents for data extraction using the
abovementioned preset criteria. Discrepancies were resolved
through discussion or input from a third reviewer. The
contributions of all authors are described in the author’s
contributions section.
Primary Outcome
The primary outcome is the number of patients from
nonrandomized studies (clinical studies and case reports)
included in the MPS reviews among all patients included
(i.e., patients from both randomized and nonrandomized
studies). The number of patients from nonrandomized
studies was calculated for each clinical type of MPS. When
there was more than one systematic review for an MPS type,
we selected the systematic review with more patients included.
We have not summed all the patients from each systematic
review because we would have counted some patients more
than once.
This measure was calculated to estimate the rate of patients
excluded from the meta-analyses and qualitative synthesis where
only randomized studies have been considered. Statistical
guidance has stated that the more the missing values, the less
the grade of evidence obtained (Little et al., 2012; Madley-Dowd
et al., 2019). Patients who were reported in more than one
nonrandomized study were counted once (Bradley et al., 2017).
However, in some randomized clinical trials, the patient follow-
up was extended after completing the study and the placebo arm
started to receive ERT, thus switching the study design to a
prospective nonrandomized design for the analysis of long-term
outcomes. As the study design and the evaluations performed in the
randomized and nonrandomized stages of these trials were different,
their patients have been considered twice (Wraith et al., 2004;
Muenzer et al., 2006; Muenzer et al., 2011; Clarke et al., 2009;
STRIVE; Investigators et al., 2014; Hendriksz et al., 2016).
Secondary Outcomes
1) We qualitatively described the differences in patients selected
and study conduct between randomized and nonrandomized
studies included in a systematic review of the same MPS type.
We evaluated these differences at four levels: treatment
schedule, patients’ characteristics, period of follow-up, and
outcomes. The recommendations for the management of
missing values in clinical trials suggest that the proportion
of missing values is not as relevant as the reason and pattern.
Thus, it was important to explore if these missing values were
at random, or if there were differences in baseline
characteristics between patients included and not included
in the analyses (Little et al., 2012; Madley-Dowd et al., 2019).
2) We described the methods used to combine data from
different study designs.
3) We estimated the number of patients who were included in a
systematic review excluding case reports among all patients
included in randomized, nonrandomized, and case reports
studies. This measure calculates the number of patients
excluded from the meta-analyses and qualitative synthesis
if case reports were not considered. As stated earlier, patients
included in both randomized trials and prospective study
extensions were considered twice (Wraith et al., 2004;
Muenzer et al., 2006; Muenzer et al., 2011; Clarke et al.,
2009; STRIVE; Investigators et al., 2014; Hendriksz et al.,
2016).
Statistical Methods
The primary variable is the rate of patients excluded from the
meta-analyses and qualitative synthesis if only randomized
studies were to be considered. The primary variable is
reported as the percentage of patients for each MPS. Statistical
guidance in single clinical trials has stated that bias is likely in
analyses with more than 10% of missing data and that if more
than 40% of data are missing in important variables, results
should only be considered as hypothesis-generating (Little et al.,
2012; Madley-Dowd et al., 2019). Thus, we tested the null
hypotheses that the rate of patients excluded when
nonrandomized studies are not considered is less than or
equal to 10% (likely bias) and that is less than or equal to
40% (evidence degraded to exploratory). Both null hypotheses
have been tested with a fixed sequence approach. First, we
compared the observed rate and the exclusion rate with a 10%
null hypothesis and continued with the next analysis (40% null
hypothesis), only if the previous assessment met the requirements
for statistical significance. We based our analysis on a one-sided
binomial test (Sampayo-Cordero et al., 2020b). This primary
objective was analyzed with a nominal alpha level of 0.025 one-
sided (equivalent to 0.05 two-sided). Multiplicity issues derived
from analyzing the rate of excluded patients in each MPS type
were corrected based on the Bonferroni method. We multiplied
the p-values by the number of MPS analyzed (U.S. Department of
Health and Human Services Food and Drug Administration et al.,
2017). In addition, we also reported the 95% confidence interval
for the rate of patients excluded.
We summarized in each systematic review selected, the
differences in patients selected and study conduct between
randomized and nonrandomized studies, describing them in a
narrative format for each MPS type. Additionally, the methods
used to combine data from different study designs were reported
in the same format.
The rate of patients excluded from the meta-analyses and
qualitative synthesis, if case reports were not considered, was also
analyzed in accordance with the primary endpoint methods.
However, multiplicity adjustment was not performed.
RESULTS
Data Search Results
Database searches through May 20, 2020, identified 64 citations
and 46 unique abstracts. Among the 46 studies identified, six were
excluded after the abstract revision because they were not MPS
studies. A total of 23 out of 40 communications with a full text
review were excluded because they did not evaluate ERT efficacy
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or safety (N  16), were not systematic reviews (N  4), or were
pharmacoeconomic studies (N  3). Thus, 17 reviews which met
the inclusion criteria and evaluated ERT efficacy or safety in
patients withMPS (N  6 in type I MPS,N  6 in type II MPS,N 
1 in type IV-A MPS, N  3 in type VI MPS, and N  1 including
patients with type I to type VI MPS) were included in the present
study. The references of all abstracts screened and the reasons for
exclusion are reported in Figure 1; Supplementary Material
Table S1. The publication years ranged between 2007 and 2019
(see Table 1).
Primary Outcome
The rate of patients missing from systematic reviews when
nonrandomized studies were excluded was significantly higher
(p < 0.001) than 40% in all MPS types (Table 1).We observed that
at least 50% of MPS patients had been recruited in
nonrandomized designs. In accordance with the rate of
missing boundaries proposed, the results of MPS systematic
reviews excluding nonrandomized trials should not be
considered confirmatory but only hypothesis generating (see
Table 1) (Little et al., 2012; Madley-Dowd et al., 2019).
Secondary Outcomes
Differences in Patients Included and Trials Conduct
Between Randomized and Nonrandomized Studies
Selected in Systematic Reviews
The qualitative analysis of patients included in randomized and
nonrandomized studies suggested relevant differences in dose
treatment schedule, inclusion criteria, extension of follow-up, and
outcomes evaluated between the two types of studies. Therefore,
there were some types of patients (with less frequent phenotypes,
the youngest (<6 years) and oldest patients (>50 years), and
special populations (pregnant women, infants, and suitable
patients for HSCT and intrathecal therapies)), dose schedules,
and clinically relevant outcomes (such as mortality, long-term
efficacy, and extended safety profile) that were excluded from
randomized trials. Even in the studies evaluating phase III
extended follow-up with the same patients included in the
randomized and prospective designs (placebo arm received
ERT in an extended follow-up), the nonrandomized study
provided results about long-term efficacy and safety, and
randomized trials excluded these relevant outcomes (see
Table 2).
FIGURE 1 | Flow diagram of systematic reviews that evaluated the efficacy and safety of enzyme replacement therapies in mucopolysaccharidosis.
MPS, Mucopolysaccharidosis; ERT, Enzyme replacement therapy. a One systematic review included all types of MPS patients to evaluate the pretreatment
and posttreatment prevalence and severity (Pal et al., 2015). This systematic review did not include outcomes of ERT for MPSIII and MPS IV. b We included a
congress communication evaluating enzyme replacement therapy safety in MPS II (Almeida et al., 2018). c This systematic review only includes
patients with Morquio A syndrome.
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Methods Used to Combine Data From Different Study
Designs in Each Systematic Review Selected
There were four types of strategies used to combine results from
studies of different designs in systematic reviews (see Table 3):
1) The first method was to select studies with the same design
and to exclude the other designs (only randomized trials or
only prospective nonrandomized studies). The studies
excluded are considered with a low level of evidence or
inappropriate to cover the research question (El Dib and
Pastores, 2007; El Dib, 2009; Brunelli et al., 2016; da Silva
et al., 2016; Jameson et al., 2019).
2) The second approximation was to summarize the results of the
studies with different designs and discuss the results
qualitatively (Alegra et al., 2013; Pal et al., 2015; Schrover
et al., 2017; Gomes et al., 2019).
3) The third method was to combine the results of studies with
different designs qualitatively, based on a method to assess
the strength of the evidence (very low, low, moderate, and
high) for each outcome. This approach allows to use a
reproducible methodology and to rank each outcome in
accordance with its strength of evidence (Bradley et al.,
2017; Dornelles et al., 2017; Pérez-López et al., 2017; Perez-
Lopez et al., 2018).
4) The fourth method was to define two improvement criteria.
One for individual patients included in the meta-analyses
(e.g., increase in the 6-min walk test [6-MWT] over the
baseline assessment) and another for the specific outcome
or group of patients evaluated (e.g., a significant difference
versus a 5% null hypothesis in the rate of patients with
improvement in the walk test) (Almeida et al., 2018;
Sampayo-Cordero et al., 2018; Kuiper et al., 2019;
Sampayo-Cordero et al., 2019).
Rate of Patients Excluded From Systematic Reviews if
Case Reports Were Excluded
The rate of patients missing from systematic reviews when case
reports were excluded was neither statistically higher than
40% nor higher than 10%. However, the rate of patients
tended to be statistically higher than 10% in two studies.
Importantly, the systematic reviews with the objective to
assess ERT outcomes in the overall population showed the
lowest rate of patients excluded (around 3.3%) (Bradley et al.,
2017; Gomes et al., 2019; Sampayo-Cordero et al., 2019).
Alternatively, the systematic reviews with the objective
targeting a specific patient subgroup (ERT initiation in
adult age) showed the highest rate of patients excluded
(around 16%) (Pérez-López et al., 2017; Pérez-López et al.,
TABLE 1 | Rate of patients excluded from systematic review when nonrandomized studies are not included.














Types I, II, III, IV,
and VI
Pal et al. (2015) 52 281a 333 84.4 (80–88.1%) < 0.0001 < 0.0001
Type I All selected max  45 max  216 261 82.8 (77.6–87.1%) < 0.0001 < 0.0001
El Dib and Pastores, (2007) 45 0 45
Dornelles et al. (2017) 45 142a 187




Jameson et al. (2019) 45 0 45
Kuiper et al. (2019) 0 216 216
Type II All selected max  108 max  1216 1,324 91.8 (90.2–93.3%) <0.0001 <0.0001
Alegra et al. (2013) 108 110 a 218
da Silva et al. (2016) 96 0 96
Almeida et al. (2018) 108 1,216 a 1,324
Pérez-López et al. 3 27 a,c 30




Type IV-A Schrover et al. (2017) 176 173 a 349 49.6 (44.2–54.9%) <0.0001 0.0003
Type VI All selected max  46 max  362 408 88.7 (85.2–91.6%) <0.0001 <0.0001
El Dib (2009) 46 0 46
Brunelli et al. (2016) 39 0 39
Gomes et al. (2019) 0 362 362
Max: Themaximum number of patients included in a systematic review for this MPS type.We selected this method of aggregation over sum or mean, because different systematic reviews
compare the same patients and the same evaluations.
aThe studies included a randomized phase III trial and its follow-up extension. The placebo arm started to receive enzyme replacement therapy and thus, the study switched to a
prospective nonrandomized design for the long-term outcomes. As the study designs and evaluations performed were different, the information provided for the same patient was
different. So, these patients have been considered twice; as participants of the randomized studies and as participants of the nonrandomized studies (21–26).
bAccording to the study objectives, only adult patients were considered (≥18 years).
cAccording to the study objectives, only adult patients were considered (≥16 years).
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TABLE 2 | Differences in patients included and trial conduct between randomized and nonrandomized studies selected in systematic reviews.
Type Parameter evaluated Main differences in patients selected and study conduct between
Randomized trials Nonrandomized studies
Types I, II, III,
IV, and VI
Dose and schedule For laronidase: weekly intravenous infusions of 0.58 mg/kg Additional doses and therapies were considered (HSCT).
However, the doses and therapies evaluated at clinical trials
are the most common
For idursulfase: 0.5 mg/kg/week or every other week
MPS phenotype The study only includes randomized trials of MPS I and II
patients. Clinical trials only include Huler–Scheie and Scheie
phenotypes for MPS I and attenuated patients for MPS II.
Patients with MPS type III, IV, and VI were also evaluated
They include a broad range of phenotypes for MPS I and II.
Follow-up time Follow-up restricted to a maximum of 26 weeks in MPS I and
12 months in MPS II clinical trials. There was no evaluation of
long-term outcomes
The follow-up was extended in some studies from 2 to
6 years
Outcomes Role of ERT in the improvement of obstructive sleep apnea They also considered other outcomes: prevalence and
severity of obstructive sleep apnea and the role of HSCT.
Type I Dose and schedule Weekly intravenous infusions of 0.58 mg/kg Additional doses were weekly intravenous infusions of 0.54,
1.16, 1.2, and 1.8 mg/kg. The intrathecal administration
was also evaluated. However, the most common schedule
was weekly intravenous infusions of 0.58 mg/kg
MPS phenotype The study only includes 1 patient with hurler phenotype (later
it was reclassified at Hurler–Scheie phenotype) and 7
patients with Scheie phenotype. The most patients included
had Hurler–Scheie phenotype (n  37)
There are more patients of Hurler and Scheie phenotypes
Follow-up time Follow-up restricted to 26 weeks. No evaluation of long-term
outcomes
The follow-up was extended in most of studies to 52 weeks
and more (288 weeks). Evaluation of long-term outcomes
Outcomes 6-MWT, urinary glycosaminoglycan levels, liver and spleen
volume, forced vital capacity, articular flexion, level of
antibodies to laronidase, nocturnal hypoventilation/sleep
apnea, quality of live, adverse events, and tolerability
They also considered other outcomes: mortality, other
anatomical and organ characteristics, visual acuity,
intraocular pressure, neurological symptoms, cognitive
evaluation, clinical development, post-surgery
complications, cardiac symptoms, dermatological
outcomes, bone mineral density, other respiratory
endpoints, other cardiac endpoints, tracheal evaluation,
sleep apnea, growth evolution, earing function, and clinical
endpoints in a pregnant woman and her infant
Type II Dose and schedule 0.5 mg/kg/week or every other week of idursulfase Additional doses were weekly intravenous infusions of 0.3,
0.4, and 0.1 mg/kg idursulfase. Idursulfase beta was also
considered (0.5 and 1 mg/kg). However, the most common




Studies only include patients with attenuated phenotype Studies include more patients with severe phenotype
Follow-up time Follow-up restricted to 12 months. No evaluation of long-
term outcomes
The follow-up was extended in most of studies to
24 months and more (288 months). Evaluation of long-term
outcomes
Outcomes 6-MWT, liver and spleen size, urinary glycosaminoglycan
levels, cardiac function, pulmonary function, sleep disorders,
level of antibodies to idursulfase, adverse events, and
tolerability
They also considered other outcomes as: mortality, other
anatomical and organ characteristics, growth evolution,
quality of live, other pulmonary endpoints, other cardiac
endpoints, sleep apnea, cognitive evaluation, clinical
development, visual acuity, and neurological symptoms,
long-term adverse events, and death
Type IV-A Dose and schedule 2 mg/kg/week or every other week of elosulfase alfa The doses were the same; the study selected was an
extension from the randomized trial. However, the placebo
arm initiated ERT.
Age at ERT initiation 5–57 years 5–57 years
Follow-up time Follow-up restricted to 24 weeks. No evaluation of long-term
outcomes
The follow-up was extended to 120 weeks. Evaluation of
long-term outcomes
Outcomes 6-MWT, a 3-min stair climb test, forced vital capacity, forced
expiratory volume in 1 s, health assessment questionnaire,
maximum voluntary ventilation, height, growth, earing
function, cardiac function, visual acuity, cervical, and lumbar
spine examination, biochemical markers, urine keratan
sulfate normalization, adverse events, and tolerability
The outcomes evaluated were the same with an extended
follow-up
Type VI Dose and schedule Weekly infusions of either high (1.0 mg/kg) or low
(0.2 mg/kg) doses of galsulfase
It was not clearly specified in most studies. A 1.0 mg/kg
weekly infusion dose is assumed
Age at ERT initiation Between 5 and 29 years Between 6 weeks and 59 years
(Continued on following page)
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2018; Sampayo-Cordero et al., 2018). So, the exclusion of
clinical reports is more likely to introduce a bias in subgroup
analyses than in the results of the whole population (where
the number of assessable patients is higher than those in
subgroup analyses) (see Table 4).
DISCUSSION
Low clinical trial accrual of patients with rare diseases is an
important constraint in evidence-based clinical practice.
Additionally, the phenotypic and genotypic heterogeneity also
TABLE 2 | (Continued) Differences in patients included and trial conduct between randomized and nonrandomized studies selected in systematic reviews.
Type Parameter evaluated Main differences in patients selected and study conduct between
Randomized trials Nonrandomized studies
Follow-up time The median and maximum duration of follow-up was
11 months. No evaluation of long-term outcomes
The median duration of follow-up was 51 months (range:
6–120 months). No evaluation of long-term outcomes
Outcomes 12 and 6-MWT, a 3-min stair climb test, urinary
glycosaminoglycan levels, joint pain, joint stiffness, physical
energy level, assessment of joint range motion, hand
dexterity as evidenced by number of coins picked up in
1 min, adverse events, tolerability, and pharmacokinetics
They also considered other outcomes as: mortality, cardiac
function, lung function, visual acuity, sleep apnea, auditory
function, quality of life, cognitive development, and growth
MPS, Muchopolysaccharidosis; ERT, Enzyme replacement therapy; HSCT, hematopoietic stem cell transplant; 6-MWT, 6-min walk test; IV, Intravenous.
TABLE 3 | Methods used to combine data from different study designs in each systematic review selected.
Type Study Methods used to combine data from different study designs
Types I, II, III, IV, and VI Pal et al. (2015) They included different types of study designs and mucopolysaccharidosis. They combine in each
mucopolysaccharidosis the results of the same outcomes and types of designs in a meta-analysis. The
noncombined results were summarized and discussed
Type I El Dib and Pastores (2007) They selected one randomized study. They did not combine results from different study designs
Dornelles et al. (2017) 1) They combined the median change to baseline or the incidence of some events. Comparison between
experimental and control arms were not considered
2) Qualitative analyses included all the study designs selected. They used GRADE criteria (Guyatt et al. (2008),
(2011); Morgan et al. (2019)) to evaluate the strength of evidence for each outcome




They used the percent of clinical cases showing improvement in efficacy outcomes, or no harm in safety
outcomes after ERT initiation as a summary of the strength of evidence. A restrictive procedure to aggregate case
reports, by selecting standardized and well-defined outcomes, was proposed
Jameson et al. (2019) They selected one randomized study. They did not combine results from different study designs
Kuiper et al. (2019) 1) They graded individual patient data as normal (N) or abnormal (A), both at baseline and at follow-up (based on
reference values as reported in the articles). Patients with an abnormal baseline and follow-up (AA) were further
classified as stable, improved, or deteriorated at follow-up (AAs, AAi, and AAd)
2) They graded patient groups as improved, stable, or deteriorated based on quantitative criteria predefined in the
original articles
Type II Alegra et al. (2013) They used GRADE criteria (Guyatt et al. (2008), (2011); Morgan et al. (2019)) to evaluate the strength of evidence
for each outcome
da Silva et al. (2016) They selected one randomized study. They did not combine results from different study designs
Almeida et al. (2018) They counted the number of infusion reactions, adverse events (serious and nonserious), and deaths in each
study
Pérez-López et al. They used GRADE criteria (Guyatt et al. (2008), (2011); Morgan et al. (2019)) to evaluate the strength of evidence
for each outcome
Bradley et al. (2017) They assessed the quality and strength of evidence for each outcome
Sampayo-Cordero et al. (2019) They used the percent of clinical cases showing improvement in efficacy outcomes, or no harm in safety
outcomes after ERT initiation as a summary of the strength of evidence. A restrictive procedure to aggregate case
reports, by selecting standardized and well-defined outcomes, was proposed
Type IV-A Schrover et al. (2017) They selected two studies, the phase III clinical trial and their extension. They summarized the results from these
studies without combining the results
Additionally, the authors calculated the minimum clinically important difference in 6-MWT. They calculated it
combining the results in a variety of diseases
Type VI El Dib, (2009) They combined results from 2 randomized clinical trials. They did not select other study designs
Brunelli et al. (2016) They selected one randomized study. They did not combine results from different study designs
Gomes et al. (2019) The effectiveness of ERT was identified by a qualitative assessment of each study report. The outcomes were
classified as primary and substitutive according to the authors’ assessment
MPS, muchopolysaccharidosis; ERT, enzyme replacement therapy; GRADE, grading of recommendations assessment, development and evaluation; HSCT, hematopoietic stem cell
transplant; 6-MWT, 6-min walk test.
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produces a greater fragmentation of the disease and increases the
difficulty to generalize the results from only one study (Bradley
et al., 2017; Dornelles et al., 2017; Rath et al., 2017). Therefore, the
systematic reviews on rare diseases represent a very useful tool for
medical community to obtain maximum information from
published data and identify areas for improvement (Pérez-
López et al., 2017). Over the last years, our comprehension of
complex, heterogeneous, highly prevalent diseases has been
considerably increased due to significant improvements in
molecular and genetic medicine. On the other hand,
personalized medicine has fragmented complex diseases into
multiple molecular subtypes, each one representing a rare
disease (Bartlett and Parelukar, 2017; Jardim et al., 2017; Klein
and Gahl, 2018). Thus, the research methods derived from rare
diseases and the strategies to integrate multiple heterogeneous
data from the literature are highly relevant (Schork, 2015; Pérez-
López et al., 2017; Klein and Gahl, 2018; Sampayo-Cordero et al.,
2019).
One of the most important items when conducting a
systematic review is the assessment of the validity of studies
included according to stringent criteria. Usually reviews
emphasize the risk of bias in their results. A common practice
is to exclude nonrandomized and nonblinded designs (Higgins
et al., 2019). However, our results suggest that more than 50% of
available patients in the field of MPS are recruited in
nonrandomized studies. Methodologies managing missing data
suggested that this rate of missing values (>40%) in a usual
clinical trial enables results to be used only as hypothesis
generators (Little et al., 2012; Madley-Dowd et al., 2019). It
would be considered that missingness in a variable collected in
a clinical trial is a different concept to the exclusion of patients
from nonrandomized studies for systematic reviews. But
randomized clinical trials usually provide the strongest
methodology to evaluate the efficacy of an intervention
(Concato et al., 2000; Higgins et al., 2019). So, it is expected
that missingness rates higher than 40% also could bias the results
of a systematic review. However, we also considered that these
results alone cannot be indicative of bias. Methods for missing
data management have stated the relevance of the source of
missing data (Little et al., 2012; Madley-Dowd et al., 2019). So, we
also observed differences in the baseline characteristics of
patients, the conduct of the study, and the outcomes evaluated
between randomized and nonrandomized studies. The
randomized trials usually recruit pediatric patients (Wraith
et al., 2004; Muenzer et al., 2006). Importantly, the clinical
manifestations of MPS in adulthood are different from
pediatric patients (Lampe et al., 2019b; Stepien et al., 2020).
So, the exclusion of nonrandomized studies prevents the
assessment of the efficacy and safety of ERT in adulthood. In
accordance, previous studies stated that the selection criteria and
monitoring conditions of clinical trials usually differed from
clinical practice. On the contrary, prospective studies and case
reports are the nearest to standard clinical practice conditions
(Kahan et al., 2015; Hong et al., 2018; on behalf of the ACMG
Professional Practice and Guidelines Committee et al., 2020). We
would like to say that excluding nonrandomized studies from a
systematic review leads to exclude >50% of available patients and
most of the data reported about adult population, alternative
treatment schedules, mortality rates, long-term efficacy, and
long-term safety.
In addition, some sections of the Cochrane guidelines
recommend including only studies with high evidence that
“can estimate causality with minimal risk of bias except to
examine the case for performing a randomized trial by
describing the weakness of the available evidence” (Higgins
et al., 2019). In the same direction, some methodologists did
not defend that excluding nonrandomized studies from a
systematic review results in a selection bias. They argue that “a
biased effect estimate from a systematic review may be more
harmful to future patients than no estimate at all, particularly if
the people using the evidence to make decisions are unaware of its
limitations” (Peto et al., 1995; Higgins et al., 2019). However, this
recommendation has three important false assumptions.
First, it is assumed that a clinical trial of any research issue is
possible (e.g., the assessment of the long-term effects and
mortality of an intervention that has improved the disease
evolution cannot be carried out using a placebo control.
Therefore, no new clinical trials would be performed
regardless of how much emphasis is placed on successive
reviews (Higgins et al., 2019)).
Second, it is assumed that the lack of epidemiological data
is not harmful. However, without published evidence,
TABLE 4 | The rate of patients excluded from systematic reviews if case reports were excluded.
Type
of MPS
Studies with the same target
population








Type I Pérez-López et al. ,
Sampayo-Cordero et al. (2018a)
Adult patients 57a 11 68 16.2% (8.4–27.1%) 0.074/1
Type II Bradley et al. (2017),
Sampayo-Cordero et al. (2019)
Overall population 928a 33 961 3.4% (2.4–4.8%) 1/1
Type II Pérez-López et al. Patients > 16 years 3a 7 37 18.9% (8–35.2%) 0.072/1
Type VI Gomes et al. (2019) Overall population 350 12 362 3.3 (1.7–5.7%) 1/1
CI, confidence interval; H0, null hypothesis.
aThe studies included a randomized phase III trial and its follow-up extension. The placebo arm started to receive enzyme replacement therapy. So, the study switched to a prospective
nonrandomized design for the long-term outcomes. As the study designs and evaluations performed were different, the information provided for the same patient was different. So, these
patients have been considered twice, as participants of the randomized studies and as participants of the nonrandomized studies.
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physicians would be guided by their intuition and their
clinical experience acquired from treating a limited
number of patients. So, trials with a large sample size will
always have a lower risk of bias than trials with a limited
number of subjects (Guyatt et al., 2008; Guyatt et al., 2011;
Morgan et al., 2019).
Finally, this recommendation assumes that investigators
should only be informed of facts where causality can be clearly
established. The clinician deals with the patient and relies to a
large extent on case reports, especially in rare and ultrarare
diseases. Accordingly, there is an established tendency to
report the available information with its degree of evidence,
rather than not reporting it. The role of nonrandomized data
in medical counseling cannot be underestimated (Scarpa et al.,
2011; Morgan et al., 2019; Cardoso et al., 2020).
Overall, we consider that excluding most of the data reported
about adult population, alternative treatment schedules, mortality
rates, long-term efficacy, and long-term safety of a chronic
treatment would produce a selection bias that could be easily
quantified. In detail, if we excluded findings of nonrandomized
studies and “low-quality” trials, a unique clinical trial published in
2004 could be considered. This means ignoring the clinical
research done on this disease in the last 16 years (Jameson
et al., 2019).
The HSCT represents another form of ERT. The HSCT has
been accepted as MPS I therapy for its severe form in the early
course of the disease. However, there is not a single RCT on
HSCT in the field of MPS. Nonrandomized data have served to
establish a consensus on the best target population and its most
appropriate strategy of treatment of MPS-I patients (Scarpa et al.,
2011). The evidence for these recommendations was not the same
weight as if they were based on randomized clinical trials.
However, these recommendations have a higher degree of
evidence than the individual beliefs of a single investigator;
and they had a great utility summarizing the available
knowledge to guide clinical practice and the future
investigations (Scarpa et al., 2011; Barth and Horovitz, 2018).
Nowadays, HSCT is reconsidered as therapy in other forms of
neuronopathic MPS after the development of new treatment
techniques and the creation of umbilical cords bank and bone
marrow donor registries (Barth and Horovitz, 2018).
Accordingly, the Cochrane guidelines accept the inclusion of
nonrandomized study designs in systematic reviews under some
constraints: “i) when randomized trials are unable to address the
effects of the intervention on harm and long-term outcomes or in
specific populations or settings; or ii) for interventions that
cannot be randomized (e.g., policy change introduced in a
single or small number of jurisdictions)” (Higgins et al., 2019).
In addition, the Cochrane guidelines recognize that there is
not a general strategy for deciding which nonrandomized studies
will be included in a systematic review (section 24.2.1.3). As a
possible strategy the authors suggest including either
nonrandomized trials with best available designs or
nonrandomized studies with a strong design. As the authors
suggest, and according to our experience of investigating the
long-term outcomes in MPS, the latter strategy may lead to
exclude all available studies. So, they recommend giving
greater emphasis to the choice of the included studies (Higgins
et al., 2019).
These results highlight the relevance of rare disease registries
as valuable sources of information for systematic reviews
(Montaño et al., 2007; Beck et al., 2014; Wood et al., 2014;
Muenzer et al., 2017a, 2017b; Lampe et al., 2019a). Although
the methodology presents a higher risk of bias than clinical trials,
a global registry is the best alternative for evaluating the long-
term efficacy of ERTs and the survival of patients treated with
these therapies (Burton et al., 2017). In the absence of data from
other designs, it is reasonable to consider these data in the
systematic reviews of rare diseases, with an assessment of the
methodological flags and possible bias (Bradley et al., 2017;
Wikman-Jorgensen et al., 2020).
Usually, case reports are never included in systematic reviews,
unless the study indication is an ultrarare disease with only case
reports available (Sampayo-Cordero et al., 2018; Sampayo-
Cordero et al., 2019). However, our results suggest that the
smaller the number of patients in the reference population, the
larger the selection bias associated to excluding case reports
(Pérez-López et al., 2018; Sampayo-Cordero et al., 2018;
Sampayo-Cordero et al., 2019). Accordingly, the selection of
case reports should be considered in an MPS systematic
review if subgroup analyses were planned (Pérez-López et al.,
2017; Pérez-López et al., 2018; Sampayo-Cordero et al., 2018). In
addition, we observed that some relevant information about
treatment management was usually reported in case reports
(Lampe et al., 2019b; Stepien et al., 2020), and previous
publications has stated the relevance of case reports to
propose clinical novelties (Nakamura et al., 2014; Sampayo-
Cordero et al., 2020a).
Alternatively, including nonrandomized studies and case
reports raise important questions. The nonrandomized studies
have been commonly associated with biased effect estimates, low
scientific evidence, and low quality (Morgan et al., 2019; Higgins
et al., 2019). Additionally, the data and methods of analyses from
randomized and nonrandomized studies are quite different
making it difficult to combine both results (Higgins et al.,
2019). However, previous studies have stated that properly
conducted observational studies and aggregations of case
reports could achieve equivalent conclusions than randomized
clinical trials and meta-analyses of prospective studies (Concato
et al., 2000; Frieden, 2017; Sampayo-Cordero et al., 2018;
Sampayo-Cordero et al., 2019). Methods to grade the strength
of evidence allow incorporating the results of nonrandomized
studies into the data analysis and discussion (Guyatt et al., 2008;
Guyatt et al., 2011; Morgan et al., 2019). Accordingly, we
observed that the combination of results from different study
designs is feasible, communicating the strength of the evidence
and the possibility of bias of each recommendation (Dornelles
et al., 2017; Kuiper et al., 2019). This is the only way to contrast
the short-term efficacy and safety results of clinical trials with the
long-term outcomes (Bradley et al., 2017), mortality rates (Burton
et al., 2017), alternative treatment schedules (Pérez-López et al.,
2017; Sampayo-Cordero et al., 2019), or patient with uncommon
phenotype or clinical characteristics of other study types (Pérez-
López et al., 2017; Pérez-López et al., 2018).
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Our findings described four strategies to combine results from
different study designs in systematic reviews. The first strategy
was excluding studies with different designs (El Dib and Pastores,
2007; El Dib, 2009; Brunelli et al., 2016; da Silva et al., 2016;
Jameson et al., 2019); the second was to summarize the results and
discuss them qualitatively (Alegra et al., 2013; Pal et al., 2015;
Schrover et al., 2017; Gomes et al., 2019); the third was to
combine the results of studies based on a method which assess
the strength of the evidence (very low, low, moderate, and high)
for each outcome (GRADE) (Bradley et al., 2017; Dornelles et al.,
2017; Pérez-López et al., 2017; Perez-Lopez et al., 2018); and the
last was to rank individual patients in each study with an
improvement or deterioration criterion and combining them
quantitatively (Almeida et al., 2018; Sampayo-Cordero et al.,
2018; Kuiper et al., 2019; Sampayo-Cordero et al., 2019).
Importantly, previous reviews have stated that ranking and
aggregation of this patients’ results should be guided by the
quality assessment of studies selected and the standardization
and good definition of outputs evaluated (Sampayo-Cordero
et al., 2018; Sampayo-Cordero et al., 2019).
The second and third strategies are based on interpreting
qualitatively the results from different study designs. However,
there is an important difference between both methods. The
second method proposes to summarize all studies results and
discus them without a predefined criterion to combine them.
Thus, the interpretation of these results is equivalent to a
conventional literature review, although the bibliographic search
could be reproducible and more reliable (second strategy) (Alegra
et al., 2013; Pal et al., 2015; Schrover et al., 2017; Gomes et al., 2019).
The third method proposes to evaluate the strength of evidence for
each relevant outcome based on a predefined criterion stated in the
protocol and widely accepted. Usually, the results are reported as a
qualitative score for each outcome (invaluable, very low, low,
moderate, and high evidence grade) (Guyatt et al., 2011; Morgan
et al., 2019). So, the interpretation of the results and conclusions are
more reproducible and evidence-based. This method could be
considered a qualitative meta-analysis (third strategy) (Bradley
et al., 2017; Dornelles et al., 2017; Pérez-López et al., 2017; Pérez-
López et al., 2018). In accordance with our results, the first strategy
can lead to biased and poorly generalizable results in the context of
rare diseases. Therefore, results could only be considered as
hypothesis generators (exploratory). The second strategy conducts
the results without a preplanned strategy, so conclusions should also
be considered as exploratory. The third and fourth strategies conduct
the analyses with a preplanned and reproducible method. Therefore,
we considered them as more reliable source to draw conclusions
about the data. It is important to consider that all four methods
presented in this review assumed a quality review of the studies
selected (Dornelles et al., 2017; Pérez-López et al., 2017; Jameson et al.,
2019; Sampayo-Cordero et al., 2019). The first method will use this
revision to exclude nonrandomized studies and low-quality clinical
trials (Jameson et al., 2019). The second method will comment
differences between studies and sources of bias in results or
discussion (Dornelles et al., 2017). The third and fourth method
will report this quality evaluation in the results section (Pérez-López
et al., 2017; Pérez-López et al., 2018; Sampayo-Cordero et al., 2018;
Sampayo-Cordero et al., 2019). Thus, these combination methods do
not propose to pool results from randomized and nonrandomized
trials without carefully evaluating the study quality, with awareness
regarding the potential bias in efficacy estimates. On the contrary,
these methods propose to evaluate both the quality and
heterogeneity of the data. In the third and fourth method
authors proposed to report separate estimates from randomized
and nonrandomized studies in order to assess if the results could be
combined (Morgan et al., 2019; Higgins et al., 2019).
Additionally, conclusions from these studies could not be
considered confirmatory without any criticism. The primary source
of the data, the proper conduct of the systematic review, and the
specific research context should be considered (Higgins et al., 2019).
As it is the case with nonrandomized studies, methods to
assess the quality of case reports, to aggregate their results, to
analyze the heterogeneity, and to assess publication bias have
been also described (Sampayo-Cordero et al., 2018; Sampayo-
Cordero et al., 2019). Guidelines to homogenize and upgrade the
quality of the case reports are also published (Gagnier et al., 2013),
and methods to develop a retrieval system in which, given one case
report, one can find other case reports that report the same or very
similar main findings have been proposed (Luo et al., 2020).
To analyze the rate of patients excluded, if nonrandomized
studies were not included, we have taken advantage of previous
systematic reviews to select the individual clinical studies
analyzed in this communication. We consider that this
strategy provides two important quality control measures.
First, the searches and study selection are less affected by the
authors’ assumptions. Second, we included communications
whose quality is high enough to be selected in previous
published systematic reviews. However, an important
limitation is that new clinical studies, which were not included
in these systematic reviews, are not considered. It is important to
state that the most recent publication selected was from 2019
(Gomes et al., 2019; Sampayo-Cordero et al., 2019) and the oldest
was from 2007 (El Dib, 2009). In addition, a very recent article in
press about a systematic review and meta-analysis, aiming at the
evaluation of ERT for treatment of Hunter disease, reported
equivalent results that we have reported in this study. Most of
the studies selected were nonrandomized, and some important
outcomes such as mortality were only analyzed in prospective
observational studies (Wikman-Jorgensen et al., 2020).
An important point in our strategy for data analyses is that the
patients analyzed in randomized clinical trials and included in
nonrandomized follow-up extensions have been considered twice,
as participants of randomized and nonrandomized trials (Wraith
et al., 2004; Muenzer et al., 2006; Muenzer et al., 2011; Clarke et al.,
2009; STRIVE; Investigators et al., 2014; Hendriksz et al., 2016). This
strategy makes sense because we are not evaluating the clinical
response of each patient. We evaluated the amount of information
provided by each design. The fact that they are the same patients is
irrelevant since the design of the studies, the outcomes evaluated, and
the information provided was different.
It is usually considered that a MEDLINE search alone is not
adequate for answering relevant questions (Porter et al., 2020;
Higgins et al., 2019). Accordingly, we have increased the scope of
our search with the Cochrane and PROSPERO databases, since
they are the preferred databases to publish systematic review
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protocols. The publication of the protocol prior to the analysis is a
key recommendation from PRISMA (Stroup et al., 2000; Liberati
et al., 2009). This strategy has allowed us to find relevant congress
communications (Almeida et al., 2018). Additionally, searches in
the LILACS database are increasingly common in systemic review
searches (Membrive-Jiménez et al., 2020; Suleiman-Martos et al.,
2020). The LILACS database has previously demonstrated its
utility incorporating in systematic review’s unique contents, since
most of its indexed journals are not indexed in other databases
(Clark and Castro, 2001; Clark and Castro, 2002). Accordingly,
we found in our study additional systematic reviews in LILACS
that were not indexed in other databases (Pal et al., 2015). This
was also the case for previous studies performed on MPS and
other indications (Pérez-López et al., 2017; Sampayo-Cordero
et al., 2018; Sampayo-Cordero et al., 2019; Mösges et al., 2019).
Our study only included systematic reviews from MPS
patients. It is important to note that differences between
randomized and nonrandomized studies observed in our
analyses have also been described in other highly prevalent
and rare diseases. In addition, the research in ultrarare genetic
diseases is usually based on registry studies, analysis of public
databases, and communication of case reports. Some ultrarare
diseases have a proportion of nonrandomized studies higher than
those in our study. (Nakamura et al., 2014; Kahan et al., 2015;
Hong et al., 2018; Jansen-van der Weide et al., 2018; on behalf of
the ACMGProfessional Practice and Guidelines Committee et al.,
2020). Therefore, the recommendations obtained from this meta-
analysis could be extended to other rare diseases.
CONCLUSION
More than 50% of patients analyzed in MPS publications have
been recruited in nonrandomized studies (Bradley et al., 2017;
Dornelles et al., 2017). The baseline characteristics of the
recruited patients, the duration of follow-up, and the clinical
outcomes evaluated differed between the randomized and
nonrandomized studies (El Dib, 2009; Brunelli et al., 2016;
Gomes et al., 2019). Therefore, our findings recommend
including nonrandomized studies in the systematic reviews of
MPS to increase the representativeness of the results and avoid a
selection bias. Despite the difficulties in analyzing the results of
different designs all together, previous studies have proposed
multiple methods to combine them (Bradley et al., 2017; Pérez-
López et al., 2017; Sampayo-Cordero et al., 2018; Kuiper et al.,
2019). Additionally, results suggest the relevance of including
case reports in a systematic review, since smaller the number of
patients in the reference population, larger the selection bias
associated to excluding case reports. Therefore, the selection of
case reports should be considered in anMPS systematic review if
subgroup analyses were to be planned (Pérez-López et al., 2018;
Sampayo-Cordero et al., 2018; Sampayo-Cordero et al., 2019).
In addition, differences between randomized and
nonrandomized studies observed in our analyses are observed
in other diseases as well (Concato et al., 2000; Liberati et al.,
2009; Frieden, 2017; Hong et al., 2018). Therefore, the
recommendations obtained from this study should be
considered when conducting systematic reviews on rare
diseases.
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